Logo image of JAGX

JAGUAR HEALTH INC (JAGX) Stock Fundamental Analysis

NASDAQ:JAGX - Nasdaq - US47010C8055 - Common Stock

0.83  -0.01 (-1.24%)

Fundamental Rating

2

Taking everything into account, JAGX scores 2 out of 10 in our fundamental rating. JAGX was compared to 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of JAGX have multiple concerns. While showing a medium growth rate, JAGX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

JAGX had negative earnings in the past year.
JAGX had a negative operating cash flow in the past year.
In the past 5 years JAGX always reported negative net income.
In the past 5 years JAGX always reported negative operating cash flow.
JAGX Yearly Net Income VS EBIT VS OCF VS FCFJAGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

JAGX's Return On Assets of -64.55% is on the low side compared to the rest of the industry. JAGX is outperformed by 68.82% of its industry peers.
JAGX has a Return On Equity of -234.48%. This is in the lower half of the industry: JAGX underperforms 73.12% of its industry peers.
Industry RankSector Rank
ROA -64.55%
ROE -234.48%
ROIC N/A
ROA(3y)-93.37%
ROA(5y)-98.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JAGX Yearly ROA, ROE, ROICJAGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2K 4K 6K

1.3 Margins

The Gross Margin of JAGX (80.11%) is better than 84.95% of its industry peers.
JAGX's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for JAGX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 80.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.75%
GM growth 5Y16.19%
JAGX Yearly Profit, Operating, Gross MarginsJAGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

2

2. Health

2.1 Basic Checks

JAGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for JAGX has been reduced compared to 1 year ago.
Compared to 5 years ago, JAGX has less shares outstanding
JAGX has a better debt/assets ratio than last year.
JAGX Yearly Shares OutstandingJAGX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
JAGX Yearly Total Debt VS Total AssetsJAGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -9.08, we must say that JAGX is in the distress zone and has some risk of bankruptcy.
JAGX's Altman-Z score of -9.08 is on the low side compared to the rest of the industry. JAGX is outperformed by 72.58% of its industry peers.
A Debt/Equity ratio of 1.35 is on the high side and indicates that JAGX has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.35, JAGX is doing worse than 75.27% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.35
Debt/FCF N/A
Altman-Z -9.08
ROIC/WACCN/A
WACC3.66%
JAGX Yearly LT Debt VS Equity VS FCFJAGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M

2.3 Liquidity

JAGX has a Current Ratio of 1.84. This is a normal value and indicates that JAGX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.84, JAGX is doing worse than 62.90% of the companies in the same industry.
JAGX has a Quick Ratio of 1.36. This is a normal value and indicates that JAGX is financially healthy and should not expect problems in meeting its short term obligations.
JAGX has a worse Quick ratio (1.36) than 71.51% of its industry peers.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio 1.36
JAGX Yearly Current Assets VS Current LiabilitesJAGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 95.45% over the past year.
The Revenue has decreased by -2.25% in the past year.
The Revenue has been growing by 17.19% on average over the past years. This is quite good.
EPS 1Y (TTM)95.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.82%
Revenue 1Y (TTM)-2.25%
Revenue growth 3Y1.32%
Revenue growth 5Y17.19%
Sales Q2Q%10.49%

3.2 Future

JAGX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.40% yearly.
JAGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 110.13% yearly.
EPS Next Y86.28%
EPS Next 2Y28.32%
EPS Next 3Y22.4%
EPS Next 5YN/A
Revenue Next Year21.35%
Revenue Next 2Y30.37%
Revenue Next 3Y33.49%
Revenue Next 5Y110.13%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
JAGX Yearly Revenue VS EstimatesJAGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
JAGX Yearly EPS VS EstimatesJAGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -10M -20M -30M -40M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

JAGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for JAGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JAGX Price Earnings VS Forward Price EarningsJAGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JAGX Per share dataJAGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as JAGX's earnings are expected to grow with 22.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.32%
EPS Next 3Y22.4%

More info and screens

0

5. Dividend

5.1 Amount

JAGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JAGUAR HEALTH INC

NASDAQ:JAGX (1/22/2025, 11:47:29 AM)

0.83

-0.01 (-1.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)N/A N/A
Inst Owners1.14%
Inst Owner Change0%
Ins Owners0.02%
Ins Owner Change1.18%
Market Cap9.79M
Analysts85.71
Price Target6.12 (637.35%)
Short Float %4.66%
Short Ratio1.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-86.75%
Min EPS beat(2)-230.06%
Max EPS beat(2)56.56%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-22.38%
Min Revenue beat(2)-22.63%
Max Revenue beat(2)-22.12%
Revenue beat(4)0
Avg Revenue beat(4)-20.11%
Min Revenue beat(4)-22.63%
Max Revenue beat(4)-13.6%
Revenue beat(8)3
Avg Revenue beat(8)-5.49%
Revenue beat(12)4
Avg Revenue beat(12)-6.77%
Revenue beat(16)5
Avg Revenue beat(16)-20.25%
PT rev (1m)0%
PT rev (3m)-58.62%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-39.17%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.66%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.93
P/FCF N/A
P/OCF N/A
P/B 0.61
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-19.88
EYN/A
EPS(NY)-2.1
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.46
OCFYN/A
SpS0.89
BVpS1.36
TBVpS-0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.55%
ROE -234.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 80.11%
FCFM N/A
ROA(3y)-93.37%
ROA(5y)-98.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.75%
GM growth 5Y16.19%
F-Score4
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 1.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.83%
Cap/Sales 0.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.84
Quick Ratio 1.36
Altman-Z -9.08
F-Score4
WACC3.66%
ROIC/WACCN/A
Cap/Depr(3y)28.3%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.72%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.82%
EPS Next Y86.28%
EPS Next 2Y28.32%
EPS Next 3Y22.4%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.25%
Revenue growth 3Y1.32%
Revenue growth 5Y17.19%
Sales Q2Q%10.49%
Revenue Next Year21.35%
Revenue Next 2Y30.37%
Revenue Next 3Y33.49%
Revenue Next 5Y110.13%
EBIT growth 1Y9.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.52%
OCF growth 3YN/A
OCF growth 5YN/A